{"slug":"jiangsu-hengrui-pharmaceuticals","name":"장쑤헝루이제약","name_en":"Jiangsu Hengrui Pharmaceuticals","ticker":"600276.SS","updated_at":"2026-07-11T10:21:41.432+00:00","canonical":"https://valuechain.wiki/jiangsu-hengrui-pharmaceuticals","kicker":"SSE 50 (상해)","kicker_en":"SSE 50 (Shanghai)","lead":"중국 최대 혁신 제약사로 항암제와 조영제, 마취제 등 처방의약품을 개발·판매하는 대형 제약 기업이다. 상해거래소 SSE 50 구성종목. 밸류체인 관계·수치 데이터는 조사 전인 기본 노드로, AI 질문 수요가 관측되면 상세 노드로 승격된다.","lead_en":"China's largest innovative pharmaceutical company, developing oncology, contrast media, and anesthesia prescription drugs. SSE 50 (Shanghai) constituent. Baseline node ahead of value-chain research; promoted to a full node once AI question demand is observed.","segments":{"parts":[{"name":"항암제"},{"name":"조영제"},{"name":"마취제·기타"}],"total":"약 ¥228억 (FY2023)"},"segments_en":{"parts":[{"name":"Oncology drugs"},{"name":"Contrast agents"},{"name":"Anesthetics & others"}],"total":"approx. CN¥22.8B (FY2023)"},"returns_yearly":{"2021":-52.5,"2022":3.5,"2023":-11,"2024":19.8,"2025":30.7,"2026":-3.8},"return_asof":"2026-07-10","value_chain":{"leading":[],"benefiting":[],"analysis":null,"analysis_en":null,"analysis_asof":null},"edges":[]}